Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status.
Ankylosing spondylitis
Inflammation
Interventional studies
JAK inhibitors
Psoriatic arthritis
Smoking
Spondyloarthritis
Tofacitinib
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
25 Sep 2024
25 Sep 2024
Historique:
received:
16
05
2024
accepted:
30
07
2024
medline:
25
9
2024
pubmed:
25
9
2024
entrez:
25
9
2024
Statut:
aheadofprint
Résumé
Routine care studies of psoriatic arthritis (PsA) and ankylosing spondylitis (AS) demonstrated attenuated responses to tumor necrosis factor inhibitors in current/past versus never smokers. This post hoc analysis assessed tofacitinib efficacy and safety in patients with PsA or AS by cigarette smoking status at trial screening. Pooled data from phase 3 and long-term extension (safety only) PsA trials and phase 2 and 3 AS trials were assessed by current/past versus never smoker status. Analysis included efficacy and safety data for tofacitinib 5 (PsA/AS) and 10 (PsA only) mg twice daily (BID) or placebo, and safety data in AS for tofacitinib 2 and 10 mg BID. Efficacy outcomes included American College of Rheumatology ≥ 50% responses (ACR50) and minimal disease activity (MDA) responses to month (M)6/M3 (tofacitinib/placebo) in PsA; and ≥ 40% improvement in Assessment of SpondyloArthritis international Society responses (ASAS40) and AS Disease Activity Score (ASDAS) < 2.1 responses to week (W)16 in AS. Safety was assessed to M48/W48 (PsA/AS), adjusted for treatment/smoking status/median body mass index (BMI) status/sex/trial/treatment-smoking status interaction. PsA/AS cohorts included 342/178 current/past and 572/194 never smokers. Tofacitinib efficacy was generally greater versus placebo to M3/W6 (PsA/AS), and comparable in current/past and never smokers to M6/W16 (PsA/AS). In patients receiving ≥ 1 tofacitinib dose, adjusted treatment-emergent adverse event (TEAE)/serious AE (SAE)/discontinuation due to AE incidence rates (IRs) to M48 in PsA were higher in current/past versus never smokers; adjusted IRs to W48 in AS were higher in current/past versus never smokers for TEAEs, but similar for SAEs/discontinuation due to AEs. In both patients with PsA and AS, tofacitinib efficacy was greater versus placebo, and comparable across smoking categories. Adjusted IRs were higher in current/past versus never smokers for TEAEs, SAEs, discontinuation due to AEs in PsA, and for TEAEs in AS, complementing reports of associations between smoking and comorbidities in spondyloarthritis. Findings support increased surveillance/caution for patients with PsA or AS with smoking history. ClinicalTrials.gov: NCT01877668/NCT01882439/NCT03486457/NCT01976364/NCT01786668/NCT03502616.
Identifiants
pubmed: 39320582
doi: 10.1007/s40744-024-00711-z
pii: 10.1007/s40744-024-00711-z
doi:
Banques de données
ClinicalTrials.gov
['NCT03502616']
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–70.
doi: 10.1056/NEJMra1505557
pubmed: 28273019
Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8–18.
Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17–28.
doi: 10.1136/annrheumdis-2016-209775
pubmed: 27697765
Wieczorek M, Gwinnutt JM, Ransay-Colle M, et al. Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022;8: e002170.
doi: 10.1136/rmdopen-2021-002170
pubmed: 35351808
pmcid: 8966569
Højgaard P, Glintborg B, Hetland ML, et al. Association between tobacco smoking and response to tumour necrosis factor alpha inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 2015;74:2130–6.
doi: 10.1136/annrheumdis-2014-205389
pubmed: 25063827
Glintborg B, Højgaard P, Lund Hetland M, et al. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford). 2016;55:659–68.
doi: 10.1093/rheumatology/kev392
pubmed: 26628579
Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525–36.
doi: 10.1056/NEJMoa1615977
pubmed: 29045207
Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–50.
doi: 10.1056/NEJMoa1615975
pubmed: 29045212
Leng X, Lin W, Liu S, et al. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2023;9: e002559.
doi: 10.1136/rmdopen-2022-002559
pubmed: 36720560
pmcid: 9890804
Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol. 2021;3:E270–83.
doi: 10.1016/S2665-9913(21)00010-2
pubmed: 38279411
van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340–7.
doi: 10.1136/annrheumdis-2016-210322
pubmed: 28130206
Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80:1004–13.
doi: 10.1136/annrheumdis-2020-219601
pubmed: 33906853
Kremer JM, Greenberg JD, Turesson C, et al. Effects of smoking history on response to treatment with tofacitinib in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. 2013;64(Suppl 10):S995.
Rubin DT, Torres J, Regueiro M, et al. Association between smoking status and the efficacy and safety of tofacitinib in patients with ulcerative colitis. Crohns Colitis 360. 2024;6:otae004.
Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212–7.
doi: 10.3899/jrheum.140172
pubmed: 24882854
Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.
doi: 10.1186/1477-7525-1-79
pubmed: 14678568
pmcid: 317391
Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47–53.
doi: 10.1136/ard.2010.138594
pubmed: 21068095
Dare S, Mackay DF, Pell JP. Relationship between smoking and obesity: a cross-sectional study of 499,504 middle-aged adults in the UK general population. PLoS ONE. 2015;10: e0123579.
doi: 10.1371/journal.pone.0123579
pubmed: 25886648
pmcid: 4401671
Zhao SS, Goodson NJ, Robertson S, Gaffney K. Smoking in spondyloarthritis: unravelling the complexities. Rheumatology (Oxford). 2020;59:1472–81.
doi: 10.1093/rheumatology/keaa093
pubmed: 32236486
Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int J Environ Res Public Health. 2018;15:1033.
doi: 10.3390/ijerph15051033
pubmed: 29883409
pmcid: 5982072
Venetsanopoulou AI, Voulgari PV, Drosos AA. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Rev Clin Immunol. 2022;18:485–93.
doi: 10.1080/1744666X.2022.2064275
pubmed: 35535405
Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7: e001595.
doi: 10.1136/rmdopen-2021-001595
pubmed: 34045358
pmcid: 8162077
Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum. 2015;44:551–5.
doi: 10.1016/j.semarthrit.2014.10.007
pubmed: 25455683
Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12–29.
doi: 10.1111/jdv.12163
pubmed: 23845149
Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326–32.
doi: 10.1136/annrheumdis-2014-205675
pubmed: 25351522
Papagoras C, Voulgari PV, Drosos AA. Cardiovascular disease in spondyloarthritides. Curr Vasc Pharmacol. 2020;18:473–87.
doi: 10.2174/1570161117666190426164306
pubmed: 31330576
Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029–49.
doi: 10.2147/TCRM.S138000
pubmed: 30464484
pmcid: 6225907
Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2019;15:41–8.
doi: 10.1080/1744666X.2019.1543591
pubmed: 30380949
Zhao S, Jones GT, Macfarlane GJ, et al. Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Rheumatology (Oxford). 2019;58:811–9.
doi: 10.1093/rheumatology/key371
pubmed: 30561738
Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82:901–10.
doi: 10.1136/ard-2022-223715
pubmed: 36931693
Moltó A, Nikiphorou E. Comorbidities in spondyloarthritis. Front Med (Lausanne). 2018;5:62.
doi: 10.3389/fmed.2018.00062
pubmed: 29594122
Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rhematol. 2019;71:5–32.
doi: 10.1002/art.40726